var data={"title":"Prurigo nodularis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Prurigo nodularis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/contributors\" class=\"contributor contributor_credentials\">Kalman Watsky, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/contributors\" class=\"contributor contributor_credentials\">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 08, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H21099279\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prurigo nodularis (PN) is an uncommon, chronic skin disorder affecting primarily older adults and is characterized by symmetrically distributed, multiple, firm, pruritic nodules. PN occurs in patients with chronic pruritus and is frequently associated with a history of atopic dermatitis [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>PN will be discussed in this topic. Other skin conditions associated with chronic pruritus, including atopic dermatitis, scabies, lichen planus, and bullous pemphigoid, are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pruritus-etiology-and-patient-evaluation\" class=\"medical medical_review\">&quot;Pruritus: Etiology and patient evaluation&quot;</a> and <a href=\"topic.htm?path=pruritus-overview-of-management\" class=\"medical medical_review\">&quot;Pruritus: Overview of management&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=scabies-epidemiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Scabies: Epidemiology, clinical features, and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=lichen-planus\" class=\"medical medical_review\">&quot;Lichen planus&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H21099286\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incidence and prevalence of PN are not known. PN can occur in all age groups but primarily affects older adults. In a review of 108 cases of PN, the median age was 62 years [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/3\" class=\"abstract_t\">3</a>]. Both sexes are equally affected [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/4\" class=\"abstract_t\">4</a>].</p><p>In approximately half of all cases, PN is associated with a history of atopic dermatitis [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/3\" class=\"abstract_t\">3</a>]. Patients with atopic dermatitis may have PN at an earlier age than nonatopic patients [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/5\" class=\"abstract_t\">5</a>]. PN occurs in approximately 5 percent of patients with human immunodeficiency virus (HIV) infection, particularly among individuals with a CD4+ count &lt;200 <span class=\"nowrap\">cells/mm<sup>3</span> </sup>[<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/6,7\" class=\"abstract_t\">6,7</a>]. </p><p class=\"headingAnchor\" id=\"H21099293\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PN is a distinctive reaction pattern occurring in a subset of patients with chronic pruritus, as a result of continuous scratching over a prolonged period of time. Predisposing factors include dermatologic, systemic, neurologic, and psychiatric diseases associated with severe pruritus. However, the exact pathogenesis of PN remains unclear. Earlier studies noted an increased number of nerve fibers in the papillary dermis, suggesting a neurocutaneous component in the pathogenesis of PN [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/8\" class=\"abstract_t\">8</a>]. Nerve growth factor (NGF) and its receptor, tyrosine kinase A (TrkA), are overexpressed in PN lesions and may be associated with the increased release and accumulation of neuropeptides, such as substance P and calcitonin gene-related peptide [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/9-11\" class=\"abstract_t\">9-11</a>]. Mast cells, which are known to release NGF, are seen in close vicinity to nerves expressing TrkA [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>Subsequent studies have noted a hypoplasia of intraepidermal nerves in PN. An immunohistochemical study of 53 patients with PN found that intraepidermal nerve fiber density is reduced in lesional and nonlesional skin of patients with PN. A subsequent study of 30 patients with PN confirmed a significant reduction of intraepidermal nerve fiber density in lesional and perilesional skin compared with normal and healed skin. These findings suggest that PN may represent a form of subclinical, cutaneous small fiber neuropathy [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/14-16\" class=\"abstract_t\">14-16</a>].</p><p>The role of T helper 1 (Th1) and T helper 2 (Th2) cytokines in the pathogenesis of PN also has been evaluated by examining the cytokine signatures in the epidermis in 22 cases of PN, using the signal transducers and activators of transcription (STAT) 1, 3, and 6 [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/17\" class=\"abstract_t\">17</a>]. In 19 of 22 cases, the entire epidermis stained with anti-pSTAT 6, a marker for the Th2 cytokines interleukin (IL)-4, IL-5, and IL-13. Only eight cases showed scattered staining with anti-pSTAT 1, a marker for the Th1 cytokines interferon-gamma and IL-27. These findings suggest that Th2 cytokines play a principal role in the pathogenesis of PN.</p><p class=\"headingAnchor\" id=\"H939496363\"><span class=\"h1\">ASSOCIATED CONDITIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately half of all cases of PN have a history of atopic dermatitis [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/3\" class=\"abstract_t\">3</a>]. Systemic diseases (eg, diabetes, chronic renal failure, hepatitis C, gluten enteropathy, human immunodeficiency virus [HIV] infection), psychiatric disorders (eg, anxiety, depression), and emotional stress have also been reported in patients with PN [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/3,18-21\" class=\"abstract_t\">3,18-21</a>]. However, the exact role of these underlying conditions in the development of PN is unclear.</p><p class=\"headingAnchor\" id=\"H6984368\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histopathology of PN shows thick, compact orthohyperkeratosis; irregular epidermal hyperplasia or pseudoepitheliomatous hyperplasia; focal parakeratosis with irregular acanthosis; diminished nerve fiber density; and a nonspecific dermal infiltrate containing lymphocytes, macrophages, eosinophils, and neutrophils (<a href=\"image.htm?imageKey=DERM%2F86963\" class=\"graphic graphic_picture graphicRef86963 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/22-25\" class=\"abstract_t\">22-25</a>]. A hair follicle may be seen in the center of the lesion [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/26\" class=\"abstract_t\">26</a>].</p><p class=\"headingAnchor\" id=\"H21099300\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PN typically presents with firm, dome-shaped, itchy nodules ranging in size from a few millimeters to several centimeters and often symmetrically distributed on the extensor surfaces of the arms and legs and on the trunk (<a href=\"image.htm?imageKey=DERM%2F86816%7EDERM%2F66268%7EDERM%2F53475%7EDERM%2F86964\" class=\"graphic graphic_picture graphicRef86816 graphicRef66268 graphicRef53475 graphicRef86964 \">picture 2A-D</a>). Nodules can be flesh-colored, erythematous, or <span class=\"nowrap\">brown/black</span> and range in number from few to hundreds (<a href=\"image.htm?imageKey=DERM%2F86817\" class=\"graphic graphic_picture graphicRef86817 \">picture 2E</a>).</p><p>The extensor surfaces of the extremities are characteristically involved, but the upper back, abdomen, and sacrum also can be involved; the difficult-to-reach upper midback area is usually spared (&quot;butterfly&quot; sign) [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/25\" class=\"abstract_t\">25</a>]. The palms, soles, face, and flexural areas are rarely involved.</p><p>Pruritus is always severe and distressing; it can be paroxysmal, sporadic, or continuous and is worsened by heat, sweating, or irritation from clothing. In many cases, the cause of pruritus is unknown.</p><p>In some patients, a coexistent pruritic skin condition (eg, atopic dermatitis, xerosis) may be the initial cause of pruritus. Rarely, PN may be the presenting symptom of a systemic disease, such as infection with human immunodeficiency virus (HIV) or mycobacteria, parasitic infestation, or lymphoma [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/7,27-30\" class=\"abstract_t\">7,27-30</a>].</p><p>A clinical presentation characterized by the coexistence of prurigo nodules and multiple keratoacanthomas on pruritic, actinically damaged skin has been described in several patients [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/31\" class=\"abstract_t\">31</a>]. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21099314\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of PN is clinical, based upon a history of chronic, severe pruritus and the clinical finding of characteristic excoriated, nodular lesions often symmetrically distributed (<a href=\"image.htm?imageKey=DERM%2F86817%7EDERM%2F53475%7EDERM%2F66268%7EDERM%2F86816\" class=\"graphic graphic_picture graphicRef86817 graphicRef53475 graphicRef66268 graphicRef86816 \">picture 2A-C, 2E</a>). A skin biopsy is not routinely performed to confirm the diagnosis. </p><p>However, a skin biopsy may be indicated in cases where the clinical diagnosis is in question or there is a poor response to first-line therapies. Immunofluorescence studies and enzyme-linked immunosorbent assay to detect the presence of circulating autoantibodies against bullous pemphigoid may be performed if suggested by history and clinical examination. (See <a href=\"#H6984633\" class=\"local\">'Differential diagnosis'</a> below.)</p><p>In patients with PN who do not have a history of atopic dermatitis or other pruritic skin conditions, systemic causes of chronic pruritus (eg, chronic kidney disease, liver disease, thyroid disease, human immunodeficiency virus [HIV] infection, parasitic infestation, malignancy) should be investigated. The initial laboratory and imaging evaluation may include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood cell count</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liver function tests</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blood urea nitrogen and creatinine</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thyroid-stimulating hormone</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HIV test</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urinalysis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stool examination for ova and parasites</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest radiograph</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pruritus-etiology-and-patient-evaluation\" class=\"medical medical_review\">&quot;Pruritus: Etiology and patient evaluation&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H6984633\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Skin diseases that may mimic PN include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Acquired reactive perforating dermatoses</strong> &ndash; Acquired reactive perforating dermatoses are a group of rare skin disorders most commonly associated with chronic renal failure and diabetes mellitus, characterized by transepithelial elimination of dermal material. They present with pruritic, dome-shaped, umbilicated papules with a central keratinous plug located on the trunk and limbs (<a href=\"image.htm?imageKey=DERM%2F86478%7EDERM%2F86829%7EDERM%2F86830%7EDERM%2F86831\" class=\"graphic graphic_picture graphicRef86478 graphicRef86829 graphicRef86830 graphicRef86831 \">picture 3A-D</a>) [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/32\" class=\"abstract_t\">32</a>]. Histology reveals a cup-shaped depression of the epidermis filled with a plug consisting of keratin, collagen, and inflammatory debris. The underlying epidermis shows fine slits through which basophilic collagen fibers in vertical orientation are extruded. (See <a href=\"topic.htm?path=perforating-dermatoses#H3793147941\" class=\"medical medical_review\">&quot;Perforating dermatoses&quot;, section on 'Acquired perforating dermatosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pemphigoid nodularis</strong> &ndash; Pemphigoid nodularis is a rare variant of bullous pemphigoid (BP) characterized by pruritic nodules, papules, or plaques that mimic PN clinically and histologically [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/23,33\" class=\"abstract_t\">23,33</a>]. The diagnosis is confirmed by direct immunofluorescence, showing linear immunoglobulin G (IgG) <span class=\"nowrap\">and/or</span> complement component 3 (C3) staining along the basement membrane zone, and presence of circulating autoantibodies against BP antigens [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/33,34\" class=\"abstract_t\">33,34</a>]. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Nodular scabies</strong> &ndash; A history of exposure and histologic examination can usually differentiate PN from nodular scabies (<a href=\"image.htm?imageKey=DERM%2F60849%7EDERM%2F75169%7EDERM%2F83093\" class=\"graphic graphic_picture graphicRef60849 graphicRef75169 graphicRef83093 \">picture 4A-C</a>). Usually, other typical signs of scabies, such as burrows and excoriations, are present. (See <a href=\"topic.htm?path=scabies-epidemiology-clinical-features-and-diagnosis#H9\" class=\"medical medical_review\">&quot;Scabies: Epidemiology, clinical features, and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hypertrophic lichen planus</strong> &ndash; Hypertrophic lichen planus is a variant of lichen planus characterized by the presence of thick, hyperkeratotic plaques, often on the anterior aspect of the legs (<a href=\"image.htm?imageKey=DERM%2F54396\" class=\"graphic graphic_picture graphicRef54396 \">picture 5</a>). Histology can clarify the diagnosis. (See <a href=\"topic.htm?path=lichen-planus\" class=\"medical medical_review\">&quot;Lichen planus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Multiple keratoacanthomas</strong> &ndash; Multiple keratoacanthomas are a feature of several rare familial or sporadic disorders (<a href=\"image.htm?imageKey=DERM%2F76410\" class=\"graphic graphic_table graphicRef76410 \">table 1</a>), including Ferguson-Smith syndrome and Grzybowski syndrome (<a href=\"image.htm?imageKey=DERM%2F50780\" class=\"graphic graphic_picture graphicRef50780 \">picture 6</a>) [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/35\" class=\"abstract_t\">35</a>]. The absence of pruritus, histologic features, and clinical course differentiate multiple keratoacanthomas from PN. (See <a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis#H2295938\" class=\"medical medical_review\">&quot;Keratoacanthoma: Epidemiology, risk factors, and diagnosis&quot;, section on 'Multiple keratoacanthomas'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Epidermolysis bullosa pruriginosa</strong> &ndash; Epidermolysis bullosa (EB) pruriginosa is a rare, localized variant of dystrophic EB characterized by skin fragility, intense pruritus, and skin lesions resembling hypertrophic lichen planus or PN [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/36,37\" class=\"abstract_t\">36,37</a>]. The clinical suspicion of inherited EB needs to be confirmed by appropriate immunofluorescence studies. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-classification-and-clinical-features-of-epidermolysis-bullosa#H476124\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, classification, and clinical features of epidermolysis bullosa&quot;, section on 'Rare subtypes'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2648390708\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of PN is difficult and requires a multifaceted approach, involving patient education to adopt general measures to reduce skin irritation and scratching, symptomatic treatment of pruritus, and topical or systemic therapies aimed at interrupting the itch-scratch cycle and flattening the skin lesions. Topical and systemic therapies for PN have not been adequately evaluated in randomized trials. Evidence for their use is mainly based upon small case series and clinical experience.</p><p class=\"headingAnchor\" id=\"H4003445471\"><span class=\"h2\">Symptomatic control of pruritus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with PN, gentle skin care using mild cleansers for bathing or showering and applying emollients multiple times per day to soothe the skin and reduce dryness should be encouraged. Additional relief can be provided by lotions that provide a cooling sensation on the skin, such as <a href=\"topic.htm?path=calamine-lotion-drug-information\" class=\"drug drug_general\">calamine lotion</a> or lotions containing menthol and <a href=\"topic.htm?path=camphor-drug-information\" class=\"drug drug_general\">camphor</a>, and those containing <a href=\"topic.htm?path=pramoxine-drug-information\" class=\"drug drug_general\">pramoxine</a> hydrochloride, a local anesthetic.</p><p>To minimize the consequences of scratching and avoid excoriations, patients should keep their nails short and may wear gloves at night. Occluding the involved areas with bandages (eg, Unna boots) or dressings may provide further relief. Any underlying compulsive behavior (eg, skin picking) should be treated. (See <a href=\"topic.htm?path=skin-picking-excoriation-disorder-and-related-disorders#H15211851\" class=\"medical medical_review\">&quot;Skin picking (excoriation) disorder and related disorders&quot;, section on 'Treatment'</a>.)</p><p>Pharmacologic therapy with first-generation sedating antihistamines (eg, <a href=\"topic.htm?path=hydroxyzine-drug-information\" class=\"drug drug_general\">hydroxyzine</a>, <a href=\"topic.htm?path=diphenhydramine-drug-information\" class=\"drug drug_general\">diphenhydramine</a>) administered at bedtime may be useful in controlling nocturnal pruritus. Both selective serotonin reuptake inhibitors and tricyclic antidepressants are also employed for chronic pruritus, especially when a component of depression is present. (See <a href=\"topic.htm?path=pruritus-overview-of-management\" class=\"medical medical_review\">&quot;Pruritus: Overview of management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3756764328\"><span class=\"h2\">Patients with limited disease</span></p><p class=\"headingAnchor\" id=\"H2025666639\"><span class=\"h3\">Topical and intralesional corticosteroids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with a limited number of nodular lesions, we suggest superpotent topical corticosteroids (group 1 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 2</a>)) as first-line therapy. Topical corticosteroids, such as <a href=\"topic.htm?path=clobetasol-drug-information\" class=\"drug drug_general\">clobetasol</a> dipropionate 0.05% ointment, are applied under occlusion with plastic wrap once at nighttime for at least two to four weeks, though a longer course of treatment may be needed. Twice-daily application is recommended if occlusion is not used. Once control is achieved, topical corticosteroids can be tapered to once or twice weekly and continued as a long-term maintenance regimen. </p><p>The efficacy of topical corticosteroids for the treatment of PN has not been adequately evaluated in randomized trials. In a single small study including 12 patients with PN, a <a href=\"topic.htm?path=betamethasone-drug-information\" class=\"drug drug_general\">betamethasone</a> valerate 0.1% medicated tape was more effective than an anti-itch moisturizer in reducing the intensity of pruritus and provided the additional benefit of preventing scratching [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/38\" class=\"abstract_t\">38</a>].</p><p>Based upon clinical experience, intralesional injection of corticosteroids is effective in reducing pruritus and flattening the nodules. It may be a treatment option in patients who have only a few large PN lesions. <a href=\"topic.htm?path=triamcinolone-drug-information\" class=\"drug drug_general\">Triamcinolone</a> acetonide in concentrations of 5 to 20 <span class=\"nowrap\">mg/mL</span> (based upon the size of the lesion and response to therapy) is injected in the lesions every four weeks until pruritus subsides and the nodules are flattened. Once significant improvement is noted, intralesional corticosteroids can be discontinued. Early recurrences can be treated with superpotent topical corticosteroids.</p><p class=\"headingAnchor\" id=\"H2349049898\"><span class=\"h3\">Other topical therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other topical treatments that have been used with some success in patients with limited PN include topical <a href=\"topic.htm?path=capsaicin-drug-information\" class=\"drug drug_general\">capsaicin</a>, topical calcineurin inhibitors, and topical vitamin D analogues. None of these treatments has been adequately evaluated in randomized trials, and their use is based upon clinical experience and limited evidence from small observational studies.</p><p>Topical <a href=\"topic.htm?path=capsaicin-drug-information\" class=\"drug drug_general\">capsaicin</a> may be a treatment option for motivated patients willing to adhere to a time-consuming schedule. Topical capsaicin 0.025% cream is applied four to six times per day for two weeks to up to several months, as tolerated. </p><p>Topical <a href=\"topic.htm?path=capsaicin-drug-information\" class=\"drug drug_general\">capsaicin</a> exerts an analgesic and antipruritic effect by inducing the depletion of the neuropeptide substance P from local sensory nerve terminals in the skin, degeneration of epidermal nerve fibers, and desensitization of nociceptive nerve endings [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/39,40\" class=\"abstract_t\">39,40</a>]. In one study, 33 patients with PN were treated with topical capsaicin 0.025 to 0.3% four to six times per day for 2 weeks up to 10 months [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/41\" class=\"abstract_t\">41</a>]. Complete remission of pruritus was reported by all patients within 12 days of treatment. The nodules flattened and softened within two months in 24 patients. However, pruritus and skin nodules recurred in 16 patients upon discontinuation of treatment.</p><p>Other topical treatments reported as beneficial in small case series include topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, topical <a href=\"topic.htm?path=pimecrolimus-drug-information\" class=\"drug drug_general\">pimecrolimus</a>, topical vitamin D analogues (eg, <a href=\"topic.htm?path=calcipotriol-calcipotriene-drug-information\" class=\"drug drug_general\">calcipotriol</a>, tacalcitol), and a compounded mixture of topical <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a>, <a href=\"topic.htm?path=amitriptyline-drug-information\" class=\"drug drug_general\">amitriptyline</a>, and <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/42-46\" class=\"abstract_t\">42-46</a>].</p><p class=\"headingAnchor\" id=\"H1250466930\"><span class=\"h2\">Patients with widespread or recalcitrant disease</span></p><p class=\"headingAnchor\" id=\"H1835802151\"><span class=\"h3\">Phototherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with widespread disease and for those with recalcitrant disease that does not respond to topical or intralesional corticosteroids, we suggest narrowband ultraviolet B (NBUVB) phototherapy as first-line therapy. NBUVB is administered two to three times weekly for up to 10 weeks in combination with topical corticosteroids. Oral antihistamines, the tricyclic antidepressants <a href=\"topic.htm?path=doxepin-drug-information\" class=\"drug drug_general\">doxepin</a> or <a href=\"topic.htm?path=amitriptyline-drug-information\" class=\"drug drug_general\">amitriptyline</a>, or <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a><span class=\"nowrap\">/<a href=\"topic.htm?path=pregabalin-drug-information\" class=\"drug drug_general\">pregabalin</a></span> may be given as adjunctive treatment to control pruritus. Emollients and topical corticosteroids may also be used as needed.</p><p>Psoralen plus ultraviolet A (PUVA) can be an alternative form of phototherapy if NBUVB is not available. (See <a href=\"topic.htm?path=uvb-therapy-broadband-and-narrowband\" class=\"medical medical_review\">&quot;UVB therapy (broadband and narrowband)&quot;</a> and <a href=\"topic.htm?path=psoralen-plus-ultraviolet-a-puva-photochemotherapy\" class=\"medical medical_review\">&quot;Psoralen plus ultraviolet A (PUVA) photochemotherapy&quot;</a>.)</p><p>Limited evidence for efficacy of phototherapy, including NBUVB, systemic and <span class=\"nowrap\">bath/topical</span> PUVA, ultraviolet A1 (UVA1), and monochromatic 308 nm excimer light, for the treatment of PN is derived from small observational studies and a single randomized trial [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/47-52\" class=\"abstract_t\">47-52</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study, 63 patients with PN were treated with topical PUVA [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/51\" class=\"abstract_t\">51</a>]. Approximately 80 percent of patients improved after the first treatment cycle of two to four weeks.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another study, 22 patients with PN were randomized to use bath PUVA or bath PUVA plus targeted 308 nm excimer laser therapy. Six of 11 patients receiving bath PUVA alone and 7 of 10 receiving combined therapy had complete clearance [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/49\" class=\"abstract_t\">49</a>]. Patients assigned to bath PUVA alone received an average of 20 treatment sessions, whereas patients assigned to combination therapy received an average of 10 bath PUVA sessions.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NBUVB therapy was used to treat 10 patients with recalcitrant PN [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/52\" class=\"abstract_t\">52</a>]. Improvement of skin lesions was reported in all patients after a median number of 16 weekly treatments.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Monochromatic excimer light (308 nm) laser therapy induced partial or complete remission in 11 patients with PN after an average of 7.5 treatments [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A modified Goeckerman regimen was successfully used in a small study of four patients with recalcitrant PN who had failed previous treatment with standard NBUVB and broadband UVB therapy [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/53\" class=\"abstract_t\">53</a>]. The regimen consisted of daily broadband UVB therapy followed by application of crude <a href=\"topic.htm?path=coal-tar-drug-information\" class=\"drug drug_general\">coal tar</a> and topical corticosteroids under occlusion for four hours.</p><p/><p class=\"headingAnchor\" id=\"H1733895967\"><span class=\"h3\">Systemic therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with widespread or recalcitrant PN who fail to respond to phototherapy and those for whom phototherapy is not feasible may benefit from systemic treatments. These include systemic immunosuppressants, <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a>, <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a>, and anticonvulsants [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/54\" class=\"abstract_t\">54</a>]. These treatments are associated with potential significant toxicity, and their efficacy in patients with recalcitrant PN has not been established. There is limited evidence to support their use based upon a few small observational studies.</p><p class=\"headingAnchor\" id=\"H513342959\"><span class=\"h4\">Systemic immunosuppressants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Low-dose <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (7.5 to 20 mg per week) or oral <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> (3 to 5 <span class=\"nowrap\">mg/kg</span> per day) may be beneficial in patients with recalcitrant PN, based upon clinical experience and a few small observational studies.</p><p>In a series of 13 patients with PN resistant to conventional therapies, low-dose <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (7.5 to 20 mg per week) was used for a minimum of six months. Ten patients achieved remission or marked improvement, measured as a reduction of the number and severity of skin lesions and pruritus [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/55\" class=\"abstract_t\">55</a>].</p><p>Oral <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> has been shown to induce rapid control of pruritus in patients with recalcitrant PN [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/56-58\" class=\"abstract_t\">56-58</a>]. In one study including 14 patients treated with cyclosporine 3 to 5 <span class=\"nowrap\">mg/kg</span> per day, 10 patients reported a &quot;very good response&quot; after an average treatment time of 2.7 months [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/57\" class=\"abstract_t\">57</a>]. In another report, eight patients with PN refractory to multiple topical and systemic therapies were treated with cyclosporine 2 to 4 <span class=\"nowrap\">mg/kg</span> per day for 2 to 48 months; six achieved remission (absence of active or new lesions) after the first two to four weeks of treatment [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/58\" class=\"abstract_t\">58</a>]. However, long-term treatment with cyclosporine is limited by adverse effects, such as elevation of blood pressure and serum creatinine.</p><p class=\"headingAnchor\" id=\"H1125741386\"><span class=\"h4\">Thalidomide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In selected patients with refractory disease, a trial of <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> may be considered. However, thalidomide is teratogenic, and its use is associated with a dose-dependent risk of peripheral neuropathy that may be nonreversible, thromboembolism, and neutropenia. In the United States, patient and provider participation in the <a href=\"http://www.thalomidrems.com/&amp;token=T4slFgMKaJb+0Y4X17ZdcjWTbOgnOXLKU4lzNfk6RFiKCpp8zzrVl941p+yMNRBC&amp;TOPIC_ID=13667\" target=\"_blank\" class=\"external\">THALOMID Risk Evaluation and Mitigation Strategy (REMS) program</a> is mandatory to obtain and dispense thalidomide.</p><p><a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">Thalidomide</a> is thought to have sedative, immunomodulatory, anti-inflammatory, and antiangiogenic properties [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/59\" class=\"abstract_t\">59</a>]. Thalidomide has been used for the treatment of PN in both immunocompetent patients and in patients with human immunodeficiency virus (HIV) infection [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/60-65\" class=\"abstract_t\">60-65</a>]. In a retrospective study, 42 patients with PN were treated with thalidomide at an average dose of 100 <span class=\"nowrap\">mg/day</span> for an average of two years [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/61\" class=\"abstract_t\">61</a>]. The average duration of thalidomide treatment before discontinuation due to neuropathy was 89 weeks (range: 1 week to 7.5 years). There was moderate to marked improvement in 50 percent of the patients; 12 patients showed only slight improvement or no effect.</p><p><a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">Lenalidomide</a> is a <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> analogue with more potent anti-inflammatory and antiangiogenic properties but with a reduced risk of peripheral neuropathy. Lenalidomide has been successfully used in a few patients with refractory PN [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/66-68\" class=\"abstract_t\">66-68</a>].</p><p class=\"headingAnchor\" id=\"H2982032762\"><span class=\"h4\">Other systemic treatments</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are a few reports of successful treatment of recalcitrant PN with neuromodulators, such as <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/69,70\" class=\"abstract_t\">69,70</a>] and <a href=\"topic.htm?path=pregabalin-drug-information\" class=\"drug drug_general\">pregabalin</a> [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/71-73\" class=\"abstract_t\">71-73</a>], the mu-opioid receptor antagonist <a href=\"topic.htm?path=naltrexone-drug-information\" class=\"drug drug_general\">naltrexone</a> [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/74\" class=\"abstract_t\">74</a>], the neurokinin receptor 1 agonist <a href=\"topic.htm?path=aprepitant-drug-information\" class=\"drug drug_general\">aprepitant</a> [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/75\" class=\"abstract_t\">75</a>], and a combination of <a href=\"topic.htm?path=montelukast-drug-information\" class=\"drug drug_general\">montelukast</a> and <a href=\"topic.htm?path=fexofenadine-drug-information\" class=\"drug drug_general\">fexofenadine</a> [<a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/76\" class=\"abstract_t\">76</a>].</p><p class=\"headingAnchor\" id=\"H21099351\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PN is a chronic and often intractable disease that may last for years, with a profound impact on the patient's quality of life. Complete resolution of lesions is rare, even after the itch-scratch cycle has been successfully interrupted. Recurrence is common.</p><p class=\"headingAnchor\" id=\"H21099358\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prurigo nodularis (PN) is a chronic skin disorder characterized by multiple firm, itchy nodules typically localized to the extensor surface of the extremities (<a href=\"image.htm?imageKey=DERM%2F66268%7EDERM%2F53475%7EDERM%2F86816%7EDERM%2F86817\" class=\"graphic graphic_picture graphicRef66268 graphicRef53475 graphicRef86816 graphicRef86817 \">picture 2A-C, 2E</a>). Pruritus is always severe and distressing; it can be paroxysmal, sporadic, or continuous and is worsened by heat, sweating, or irritation from clothing. (See <a href=\"#H21099279\" class=\"local\">'Introduction'</a> above and <a href=\"#H21099300\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of PN is clinical, based upon a history of chronic, severe pruritus and the clinical finding of characteristic excoriated, nodular lesions symmetrically distributed. Cutaneous and systemic causes of chronic pruritus should be investigated. (See <a href=\"#H21099314\" class=\"local\">'Diagnosis'</a> above and <a href=\"topic.htm?path=pruritus-etiology-and-patient-evaluation#H690781\" class=\"medical medical_review\">&quot;Pruritus: Etiology and patient evaluation&quot;, section on 'Etiology'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of PN is difficult and requires a multifaceted approach, involving patient education to adopt skin care measures to reduce skin irritation and scratching, symptomatic treatment of pruritus, and topical or systemic therapies aimed at interrupting the itch-scratch cycle and flattening the skin lesions. (See <a href=\"#H2648390708\" class=\"local\">'Management'</a> above and <a href=\"#H4003445471\" class=\"local\">'Symptomatic control of pruritus'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with a limited number of nodular lesions, we suggest superpotent topical corticosteroids (group 1 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 2</a>)) as first-line therapy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Intralesional injection of corticosteroids may be an additional or alternative treatment modality for patients with very few lesions. Sedating antihistamines, such <a href=\"topic.htm?path=diphenhydramine-drug-information\" class=\"drug drug_general\">diphenhydramine</a>, <a href=\"topic.htm?path=hydroxyzine-drug-information\" class=\"drug drug_general\">hydroxyzine</a>, or others, are routinely used. (See <a href=\"#H3756764328\" class=\"local\">'Patients with limited disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with widespread or recalcitrant disease, we suggest phototherapy with narrowband UVB (NBUVB) in combination with topical corticosteroids and oral antihistamines rather than systemic agents (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Topical or oral psoralen plus ultraviolet A (PUVA) can be alternative forms of phototherapy if NBUVB is not available. (See <a href=\"#H1250466930\" class=\"local\">'Patients with widespread or recalcitrant disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with widespread or recalcitrant disease who fail to respond to phototherapy and for those for whom phototherapy is not feasible, therapeutic options include <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, oral <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, or <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a>. Neuromodulators, such as <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> and <a href=\"topic.htm?path=pregabalin-drug-information\" class=\"drug drug_general\">pregabalin</a>, may be beneficial in some patients. (See <a href=\"#H1733895967\" class=\"local\">'Systemic therapies'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/1\" class=\"nounderline abstract_t\">Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005; 46:211.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/2\" class=\"nounderline abstract_t\">Zeidler C, Tsianakas A, Pereira M, et al. Chronic Prurigo of Nodular Type: A Review. Acta Derm Venereol 2018; 98:173.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/3\" class=\"nounderline abstract_t\">Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol 2013; 27:550.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/4\" class=\"nounderline abstract_t\">Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/5\" class=\"nounderline abstract_t\">Tanaka M, Aiba S, Matsumura N, et al. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology 1995; 190:269.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/6\" class=\"nounderline abstract_t\">Zancanaro PC, McGirt LY, Mamelak AJ, et al. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol 2006; 54:581.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/7\" class=\"nounderline abstract_t\">Magand F, Nacher M, Cazorla C, et al. Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana. Trans R Soc Trop Med Hyg 2011; 105:401.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/8\" class=\"nounderline abstract_t\">Harris B, Harris K, Penneys NS. Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis. J Am Acad Dermatol 1992; 26:56.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/9\" class=\"nounderline abstract_t\">Liang Y, Marcusson JA, Johansson O. Light and electron microscopic immunohistochemical observations of p75 nerve growth factor receptor-immunoreactive dermal nerves in prurigo nodularis. Arch Dermatol Res 1999; 291:14.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/10\" class=\"nounderline abstract_t\">Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. Arch Dermatol Res 2002; 293:614.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/11\" class=\"nounderline abstract_t\">Ikoma A, Steinhoff M, St&auml;nder S, et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7:535.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/12\" class=\"nounderline abstract_t\">Liang Y, Marcusson JA, Jacobi HH, et al. Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. J Cutan Pathol 1998; 25:189.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/13\" class=\"nounderline abstract_t\">Perez GL, Peters MS, Reda AM, et al. Mast cells, neutrophils, and eosinophils in prurigo nodularis. Arch Dermatol 1993; 129:861.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/14\" class=\"nounderline abstract_t\">Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol 2011; 165:85.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/15\" class=\"nounderline abstract_t\">Bobko S, Zeidler C, Osada N, et al. Intraepidermal Nerve Fibre Density is Decreased in Lesional and Inter-lesional Prurigo Nodularis and Reconstitutes on Healing of Lesions. Acta Derm Venereol 2016; 96:404.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/16\" class=\"nounderline abstract_t\">Zeidler C, St&auml;nder S. The pathogenesis of Prurigo nodularis--'Super-Itch' in exploration. Eur J Pain 2016; 20:37.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/17\" class=\"nounderline abstract_t\">Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol 2011; 165:990.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/18\" class=\"nounderline abstract_t\">Zelickson BD, McEvoy MT, Fransway AF. Patch testing in prurigo nodularis. Contact Dermatitis 1989; 20:321.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/19\" class=\"nounderline abstract_t\">Schneider G, Hockmann J, St&auml;nder S, et al. Psychological factors in prurigo nodularis in comparison with psoriasis vulgaris: results of a case-control study. Br J Dermatol 2006; 154:61.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/20\" class=\"nounderline abstract_t\">Dazzi C, Erma D, Piccinno R, et al. Psychological factors involved in prurigo nodularis: A pilot study. J Dermatolog Treat 2011; 22:211.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/21\" class=\"nounderline abstract_t\">J&oslash;rgensen KM, Egeberg A, Gislason GH, et al. Anxiety, depression and suicide in patients with prurigo nodularis. J Eur Acad Dermatol Venereol 2017; 31:e106.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/22\" class=\"nounderline abstract_t\">Weigelt N, Metze D, St&auml;nder S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol 2010; 37:578.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/23\" class=\"nounderline abstract_t\">Powell AM, Albert S, Gratian MJ, et al. Pemphigoid nodularis (non-bullous): a clinicopathological study of five cases. Br J Dermatol 2002; 147:343.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/24\" class=\"nounderline abstract_t\">Mattila JO, Vornanen M, Katila ML. Histopathological and bacteriological findings in prurigo nodularis. Acta Derm Venereol 1997; 77:49.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/25\" class=\"nounderline abstract_t\">Rowland Payne CM, Wilkinson JD, McKee PH, et al. Nodular prurigo--a clinicopathological study of 46 patients. Br J Dermatol 1985; 113:431.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/26\" class=\"nounderline abstract_t\">Miyauchi H, Uehara M. Follicular occurrence of prurigo nodularis. J Cutan Pathol 1988; 15:208.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/27\" class=\"nounderline abstract_t\">Jacob CI, Patten SF. Strongyloides stercoralis infection presenting as generalized prurigo nodularis and lichen simplex chronicus. J Am Acad Dermatol 1999; 41:357.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/28\" class=\"nounderline abstract_t\">Shelnitz LS, Paller AS. Hodgkin's disease manifesting as prurigo nodularis. Pediatr Dermatol 1990; 7:136.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/29\" class=\"nounderline abstract_t\">Torchia D, Caproni M, Del Bianco E, et al. Linear IgA disease presenting as prurigo nodularis. Br J Dermatol 2006; 155:479.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/30\" class=\"nounderline abstract_t\">Savoia F, Casadio C, Tabanelli M, et al. Prurigo nodularis as the first manifestation of a chronic autoimmune cholestatic hepatitis. Int J Dermatol 2011; 50:1588.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/31\" class=\"nounderline abstract_t\">Wu TP, Miller K, Cohen DE, Stein JA. Keratoacanthomas arising in association with prurigo nodules in pruritic, actinically damaged skin. J Am Acad Dermatol 2013; 69:426.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/32\" class=\"nounderline abstract_t\">Saray Y, Se&ccedil;kin D, Bilezik&ccedil;i B. Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol 2006; 20:679.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/33\" class=\"nounderline abstract_t\">Zhang W, Liu Y, Li C. Generalised nodules in pemphigoid nodularis. Lancet 2017; 389:1930.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/34\" class=\"nounderline abstract_t\">Tashiro H, Arai H, Hashimoto T, et al. Pemphigoid nodularis: two case studies and analysis of autoantibodies before and after the development of generalized blistering. J Nippon Med Sch 2005; 72:60.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/35\" class=\"nounderline abstract_t\">Kwiek B, Schwartz RA. Keratoacanthoma (KA): An update and review. J Am Acad Dermatol 2016; 74:1220.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/36\" class=\"nounderline abstract_t\">Kim WB, Alavi A, Pope E, Walsh S. Epidermolysis Bullosa Pruriginosa: Case Series and Review of the Literature. Int J Low Extrem Wounds 2015; 14:196.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/37\" class=\"nounderline abstract_t\">Frane AV. Comment on: epidermolysis bullosa pruriginosa: a systematic review exploring genotype-phenotype correlation. Am J Clin Dermatol 2015; 16:335.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/38\" class=\"nounderline abstract_t\">Saraceno R, Chiricozzi A, Nistic&ograve; SP, et al. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J Dermatolog Treat 2010; 21:363.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/39\" class=\"nounderline abstract_t\">Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999; 81:135.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/40\" class=\"nounderline abstract_t\">Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010; 11:579.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/41\" class=\"nounderline abstract_t\">St&auml;nder S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44:471.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/42\" class=\"nounderline abstract_t\">Wong SS, Goh CL. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis. Arch Dermatol 2000; 136:807.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/43\" class=\"nounderline abstract_t\">St&auml;nder S, Sch&uuml;rmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag 2006; 2:213.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/44\" class=\"nounderline abstract_t\">Katayama I, Miyazaki Y, Nishioka K. Topical vitamin D3 (tacalcitol) for steroid-resistant prurigo. Br J Dermatol 1996; 135:237.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/45\" class=\"nounderline abstract_t\">Siepmann D, Lotts T, Blome C, et al. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. Dermatology 2013; 227:353.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/46\" class=\"nounderline abstract_t\">Lee HG, Grossman SK, Valdes-Rodriguez R, et al. Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability. J Am Acad Dermatol 2017; 76:760.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/47\" class=\"nounderline abstract_t\">Saraceno R, Nistic&ograve; SP, Capriotti E, et al. Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis. Photodermatol Photoimmunol Photomed 2008; 24:43.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/48\" class=\"nounderline abstract_t\">Bruni E, Caccialanza M, Piccinno R. Phototherapy of generalized prurigo nodularis. Clin Exp Dermatol 2010; 35:549.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/49\" class=\"nounderline abstract_t\">Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol 2011; 25:799.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/50\" class=\"nounderline abstract_t\">Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008; 24:19.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/51\" class=\"nounderline abstract_t\">Karvonen J, Hannuksela M. Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo. Acta Derm Venereol Suppl (Stockh) 1985; 120:53.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/52\" class=\"nounderline abstract_t\">Tamagawa-Mineoka R, Katoh N, Ueda E, Kishimoto S. Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo. J Dermatol 2007; 34:691.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/53\" class=\"nounderline abstract_t\">Sorenson E, Levin E, Koo J, Berger TG. Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis. J Am Acad Dermatol 2015; 72:e40.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/54\" class=\"nounderline abstract_t\">Tsianakas A, Zeidler C, St&auml;nder S. Prurigo Nodularis Management. Curr Probl Dermatol 2016; 50:94.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/55\" class=\"nounderline abstract_t\">Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol 2014; 39:468.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/56\" class=\"nounderline abstract_t\">Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to cyclosporin. Br J Dermatol 1995; 132:795.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/57\" class=\"nounderline abstract_t\">Siepmann D, Luger TA, St&auml;nder S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges 2008; 6:941.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/58\" class=\"nounderline abstract_t\">Wiznia LE, Callahan SW, Cohen DE, Orlow SJ. Rapid improvement of prurigo nodularis with cyclosporine treatment. J Am Acad Dermatol 2018.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/59\" class=\"nounderline abstract_t\">Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005; 153:254.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/60\" class=\"nounderline abstract_t\">Doherty SD, Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol 2008; 7:769.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/61\" class=\"nounderline abstract_t\">Andersen TP, Fogh K. Thalidomide in 42 patients with prurigo nodularis Hyde. Dermatology 2011; 223:107.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/62\" class=\"nounderline abstract_t\">Lan CC, Lin CL, Wu CS, et al. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. J Dermatol 2007; 34:237.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/63\" class=\"nounderline abstract_t\">Taefehnorooz H, Truchetet F, Barbaud A, et al. Efficacy of thalidomide in the treatment of prurigo nodularis. Acta Derm Venereol 2011; 91:344.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/64\" class=\"nounderline abstract_t\">Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch Dermatol 2004; 140:845.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/65\" class=\"nounderline abstract_t\">Lim VM, Maranda EL, Patel V, et al. A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. Dermatol Ther (Heidelb) 2016; 6:397.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/66\" class=\"nounderline abstract_t\">Kanavy H, Bahner J, Korman NJ. Treatment of refractory prurigo nodularis with lenalidomide. Arch Dermatol 2012; 148:794.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/67\" class=\"nounderline abstract_t\">Liu H, Gaspari AA, Schleichert R. Use of lenalidomide in treating refractory prurigo nodularis. J Drugs Dermatol 2013; 12:360.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/68\" class=\"nounderline abstract_t\">Ossorio-Garc&iacute;a L, Jim&eacute;nez-Gallo D, Rodr&iacute;guez-Mateos ME, et al. Treatment of prurigo nodularis with lenalidomide. Dermatol Ther 2017; 30.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/69\" class=\"nounderline abstract_t\">Gencoglan G, Inanir I, Gunduz K. Therapeutic hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther 2010; 23:194.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/70\" class=\"nounderline abstract_t\">Dereli T, Karaca N, Inanir I, Ozt&uuml;rk G. Gabapentin for the treatment of recalcitrant chronic prurigo nodularis. Eur J Dermatol 2008; 18:85.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/71\" class=\"nounderline abstract_t\">Mazza M, Guerriero G, Marano G, et al. Treatment of prurigo nodularis with pregabalin. J Clin Pharm Ther 2013; 38:16.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/72\" class=\"nounderline abstract_t\">Asplund M, Calling S, Spir&eacute;n A, Svedman C. [Prurigo nodularis--pregabalin can be considered for more severe symptoms]. Lakartidningen 2015; 112.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/73\" class=\"nounderline abstract_t\">Imai K, Kishimoto M, Tsujimoto T, et al. Successful treatment of chronic intractable itching using oral pregabalin in a patient with diabetes and systemic prurigo nodularis: a case report of an iliopsoas muscle abscess. Intern Med 2013; 52:2629.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/74\" class=\"nounderline abstract_t\">Phan NQ, Bernhard JD, Luger TA, St&auml;nder S. Antipruritic treatment with systemic &mu;-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63:680.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/75\" class=\"nounderline abstract_t\">St&auml;nder S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5:e10968.</a></li><li><a href=\"https://www.uptodate.com/contents/prurigo-nodularis/abstract/76\" class=\"nounderline abstract_t\">Shintani T, Ohata C, Koga H, et al. Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. Dermatol Ther 2014; 27:135.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13667 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21099358\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H21099279\" id=\"outline-link-H21099279\">INTRODUCTION</a></li><li><a href=\"#H21099286\" id=\"outline-link-H21099286\">EPIDEMIOLOGY</a></li><li><a href=\"#H21099293\" id=\"outline-link-H21099293\">PATHOGENESIS</a></li><li><a href=\"#H939496363\" id=\"outline-link-H939496363\">ASSOCIATED CONDITIONS</a></li><li><a href=\"#H6984368\" id=\"outline-link-H6984368\">HISTOPATHOLOGY</a></li><li><a href=\"#H21099300\" id=\"outline-link-H21099300\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H21099314\" id=\"outline-link-H21099314\">DIAGNOSIS</a></li><li><a href=\"#H6984633\" id=\"outline-link-H6984633\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H2648390708\" id=\"outline-link-H2648390708\">MANAGEMENT</a><ul><li><a href=\"#H4003445471\" id=\"outline-link-H4003445471\">Symptomatic control of pruritus</a></li><li><a href=\"#H3756764328\" id=\"outline-link-H3756764328\">Patients with limited disease</a><ul><li><a href=\"#H2025666639\" id=\"outline-link-H2025666639\">- Topical and intralesional corticosteroids</a></li><li><a href=\"#H2349049898\" id=\"outline-link-H2349049898\">- Other topical therapies</a></li></ul></li><li><a href=\"#H1250466930\" id=\"outline-link-H1250466930\">Patients with widespread or recalcitrant disease</a><ul><li><a href=\"#H1835802151\" id=\"outline-link-H1835802151\">- Phototherapy</a></li><li><a href=\"#H1733895967\" id=\"outline-link-H1733895967\">- Systemic therapies</a><ul><li><a href=\"#H513342959\" id=\"outline-link-H513342959\">Systemic immunosuppressants</a></li><li><a href=\"#H1125741386\" id=\"outline-link-H1125741386\">Thalidomide</a></li><li><a href=\"#H2982032762\" id=\"outline-link-H2982032762\">Other systemic treatments</a></li></ul></li></ul></li></ul></li><li><a href=\"#H21099351\" id=\"outline-link-H21099351\">PROGNOSIS</a></li><li><a href=\"#H21099358\" id=\"outline-link-H21099358\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13667|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/86963\" class=\"graphic graphic_picture\">- Prurigo nodularis histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/86816\" class=\"graphic graphic_picture\">- Prurigo nodularis 3</a></li><li><a href=\"image.htm?imageKey=DERM/66268\" class=\"graphic graphic_picture\">- Prurigo nodularis 2</a></li><li><a href=\"image.htm?imageKey=DERM/53475\" class=\"graphic graphic_picture\">- Prurigo nodularis 1</a></li><li><a href=\"image.htm?imageKey=DERM/86964\" class=\"graphic graphic_picture\">- Prurigo nodularis arms </a></li><li><a href=\"image.htm?imageKey=DERM/86817\" class=\"graphic graphic_picture\">- Prurigo nodularis 4</a></li><li><a href=\"image.htm?imageKey=DERM/86478\" class=\"graphic graphic_picture\">- Perforating dermatosis</a></li><li><a href=\"image.htm?imageKey=DERM/86829\" class=\"graphic graphic_picture\">- Perforating dermatosis 2</a></li><li><a href=\"image.htm?imageKey=DERM/86830\" class=\"graphic graphic_picture\">- Perforating dermatosis 3</a></li><li><a href=\"image.htm?imageKey=DERM/86831\" class=\"graphic graphic_picture\">- Perforating dermatosis 4</a></li><li><a href=\"image.htm?imageKey=DERM/60849\" class=\"graphic graphic_picture\">- Scabies axilla</a></li><li><a href=\"image.htm?imageKey=DERM/75169\" class=\"graphic graphic_picture\">- Scabies buttocks</a></li><li><a href=\"image.htm?imageKey=DERM/83093\" class=\"graphic graphic_picture\">- Scabies nodular</a></li><li><a href=\"image.htm?imageKey=DERM/54396\" class=\"graphic graphic_picture\">- Hypertrophic lichen planus lesion</a></li><li><a href=\"image.htm?imageKey=DERM/50780\" class=\"graphic graphic_picture\">- Multiple keratoacanthomas</a></li></ul></li><li><div id=\"DERM/13667|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/76410\" class=\"graphic graphic_table\">- Multiple keratoacanthoma clinical variants</a></li><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid\" class=\"medical medical_review\">Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-classification-and-clinical-features-of-epidermolysis-bullosa\" class=\"medical medical_review\">Epidemiology, pathogenesis, classification, and clinical features of epidermolysis bullosa</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=keratoacanthoma-epidemiology-risk-factors-and-diagnosis\" class=\"medical medical_review\">Keratoacanthoma: Epidemiology, risk factors, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lichen-planus\" class=\"medical medical_review\">Lichen planus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perforating-dermatoses\" class=\"medical medical_review\">Perforating dermatoses</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pruritus-etiology-and-patient-evaluation\" class=\"medical medical_review\">Pruritus: Etiology and patient evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pruritus-overview-of-management\" class=\"medical medical_review\">Pruritus: Overview of management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=psoralen-plus-ultraviolet-a-puva-photochemotherapy\" class=\"medical medical_review\">Psoralen plus ultraviolet A (PUVA) photochemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=scabies-epidemiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">Scabies: Epidemiology, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=skin-picking-excoriation-disorder-and-related-disorders\" class=\"medical medical_review\">Skin picking (excoriation) disorder and related disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=uvb-therapy-broadband-and-narrowband\" class=\"medical medical_review\">UVB therapy (broadband and narrowband)</a></li></ul></div></div>","javascript":null}